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for each month during the ﬁrst year following transplan-
tation took into account only direct costs arising from
transplantectomy (€3,153, procedural rate plus daily 
hospital rate) and dialysis (€3,687 monthly, Kupsch et al.
1998). RESULTS: Based on these data, the average
annual costs of a graft loss are calculated. Consequently,
an average patient treated with cyclosporine brand med-
ication leads to additional annual costs of €4,239 due to
graft loss. In patients treated with a generic formulation
these costs amount to €7,832. The resulting cost dif-
ferential of €3,593 per year implies that a generic
cyclosporine formulation would have to be at least 61%
cheaper than a brand regimen (currently €5,675 p.a.) in
order to be at least cost neutral. CONCLUSION: Focus-
ing only on direct costs of graft loss not including e.g.
rescue medication, the above calculation is extremely con-
servative. Cost savings potentially achievable by means of
a generic treatment regimen will most likely be consumed
by signiﬁcant costs resulting from graft loss unless the
generic is more than 61% cheaper than brand medica-
tion. This ratio will worsen considerably if the costs for
retransplantation are taken into account.
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OBJECTIVE: An economic model was developed to 
estimate the comparative cost-effectiveness of treating
unstable bladder (UB) in Belgium with alternative drug
treatments and no treatment. The model uses a one-year
timeframe and the payer (e.g., Riziv/INAMI, Sickness
funds) perspective. METHODS: The study population
included patients seeking UB treatment and was divided
into successfully treated patients (STP) and patients
failing treatment (PFT). The percentage of STP was cal-
culated from clinical efﬁcacy adjusted by annual persis-
tency. For each group of patients, direct and indirect costs
were identiﬁed, including costs for drugs, incontinence
pads, physician visits, lab tests/diagnostics, and associated
comorbidities. Resource utilization and costs were
obtained from literature, the National Health Insurance
System, Ofﬁcial Public Price Ministry Economic
Affairs/Pharmaceutical Tariﬁcation, clinical trials, and
expert medical panels. RESULTS: The prevalence of UB
sufferers in Belgium was estimated to be 3% in 2002
(approximately 303,000 people), with only 30% of those
patients seeking treatment (approximately 1% of the
Belgian population). STP used fewer pads per day, visited
physicians less frequently, had fewer lab tests/diagnostics,
and experienced fewer comorbidities than PFT. Cost
drivers in the model were comorbidities and physician
visits. Tolterodine sustained-release (TSR) had compara-
ble efﬁcacy to oxybutynin, but persistence on therapy was
higher for TSR. Therefore, effectiveness was higher for
TSR versus oxybutynin (37% for TSR, 10% for oxybu-
tynin). Effectiveness was considered 0% for no treatment.
Cost per STP was €1,167 for TSR and €2,181 for oxy-
butynin. Sensitivity analyses varying efﬁcacy and persis-
tency by 10% still resulted in a lower cost per STP for
TSR. TSR had an incremental cost-effectiveness of €816.
The “no treatment” group demonstrated the highest non-
drug costs while providing no efﬁcacy. CONCLUSION:
Tolterodine sustained-release is a more cost-effective
treatment than oxybutynin in treating UB as measured by
cost per successfully treated patient in Belgium.
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OBJECTIVES: Several researchers have estimated the
cost-effectiveness (CE) of long-acting forms of tolterodine
(TOL) and oxybutynin (OXY) in overactive bladder
(OAB). Typically, it’s assumed that effectively treated
patients consume fewer resources, including incontinence
pads, physician visits, laboratory tests, and costs related
to comorbid conditions. Claims analyses have shown a
link between the presence of OAB and higher medical
costs; however, no prospective studies have evaluated the
effect of treatment on resource consumption, and drug
acquisition cost (DAC) continues to be the focus for many
decision-makers. A head-to-head patient outcome trial
comparing TOL and OXY was recently completed, 
the Antimuscarinic Clinical Effectiveness Trial (ACET);
however, resource consumption wasn’t collected. Our
objective was to determine the CE of TOL 4mg and OXY
10mg based on DAC and effectiveness data from ACET.
METHODS: The primary effectiveness endpoint in
ACET was patient perception of improvement in their
bladder condition after eight weeks of treatment. Results
showed that 70% of TOL patients and 60% of OXY
patients reported improvement in their bladder condition
at 8 weeks. Dropout rates were 11.6% and 20.5% for
TOL and OXY, respectively. We assumed dropouts com-
pleted four weeks of treatment. The daily AWP cost of
TOL 4mg and OXY 10mg was $2.7967 and $2.6875,
respectively. RESULTS: For every 100 patients treated
with TOL and OXY, DAC is $14,752.98 and
$13,507.38, respectively. The cost per effectively treated
patient for TOL is $210.76 and $225.12 for OXY. The
incremental CE for TOL is $124.56 per additional effec-
tively treated patient. CONCLUSIONS: When only DAC
is considered, TOL is more cost-effective than OXY. If
effectively treated patients do consume fewer resources,
then the CE of TOL should be even better. Determining
